LONDON, Oct 2 (Reuters) – Europe’s medicines regulator has
endorsed a scheme to publish detailed clinical reports
underpinning new drug approvals from next year, though
campaigners for full transparency said they were concerned some
data would still be missing.
The London-based European Medicines Agency (EMA) has been at
the centre of a row about divulging trials data for the past two
years, following concerns over undisclosed data for certain
drugs such as Roche’s flu pill Tamiflu.